Free tool
FAERS Monitor: Altafluor Benox
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208582 or its brand name (Altafluor Benox, Benoxinate Hydrochloride, Fluorescein Sodium). Reports on generic versions are filed under their own applications.
Reports
9
Serious
7
78% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- confusional state2
- eye pain2
- headache2
- nausea2
- rash2
- syncope2
- abdominal pain upper1
- abnormal sensation in eye1
- blood glucose decreased1
- device calibration failure1
- disorientation1
- dizziness1
- documented hypersensitivity to administered product1
- dry eye1
- dysarthria1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device calibration failure | 1 | 44987.5 | 6949.0 | 11,034 |
| documented hypersensitivity to administered product | 1 | 2849.4 | 448.4 | 711 |
| abnormal sensation in eye | 1 | 543.8 | 85.7 | 135 |
| eye pain | 2 | 82.8 | 24.4 | 90 |
| dysarthria | 1 | 62.1 | 9.8 | 15 |
| disorientation | 1 | 59.0 | 9.3 | 14 |
| blood glucose decreased | 1 | 48.7 | 7.7 | 11 |
| dry eye | 1 | 46.8 | 7.4 | 11 |
| syncope | 2 | 46.7 | 13.8 | 50 |
| confusional state | 2 | 28.9 | 8.5 | 30 |
| abdominal pain upper | 1 | 11.4 | 1.8 | 2 |
| rash | 2 | 10.7 | 3.2 | 9 |
| headache | 2 | 7.5 | 2.2 | 6 |
| nausea | 2 | 5.9 | 1.7 | 4 |
| dizziness | 1 | 4.7 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.